Payment overview · 2025
General Payments
$1,013.55
48 reported records · 20 companies
Healthcare provider profile · identity verified
Randall Dean Barnes, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · GRANBURY, TX · NPI 1265461792
Verified facts
What the public records show
CMS Open Payments records show Randall Dean Barnes, D.O. received $1,013.55 in general payments during 2025 across 48 reported records.
Lilly USA, LLC accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $227.22 | 22.4% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $101.31 | 10.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.20 | 8.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.63 | 6.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.39 | 6.5% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $53.16 | 5.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $52.38 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.57 | 4.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.78 | 4.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.84 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.56 | 3.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.80 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.69 | 2.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.68 | 2.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $22.42 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.64 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.40 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.98 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.77 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $968.55 | 47 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $132.42 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.63 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $53.16 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $52.38 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.84 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $40.42 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 173 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 32 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 898 | 253 |
| Levothyroxine Sodium | Levothyroxine Sodium | 797 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 699 | 176 |
| Losartan Potassium | Losartan Potassium | 582 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 167 |
| Eliquis | Apixaban | 523 | 108 |
| Famotidine | Famotidine | 468 | 167 |
| Gabapentin | Gabapentin | 450 | 122 |
| Sertraline Hcl | Sertraline Hcl | 442 | 121 |
| Potassium Chloride | Potassium Chloride | 407 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 107 |
| Furosemide | Furosemide | 349 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 329 | 91 |
| Lisinopril | Lisinopril | 324 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 323 | 93 |
| Trazodone Hcl | Trazodone Hcl | 298 | 79 |
| Donepezil Hcl | Donepezil Hcl | 284 | 57 |
| Omeprazole | Omeprazole | 244 | 79 |
| Carvedilol | Carvedilol | 217 | 65 |
| Metformin Hcl | Metformin Hcl | 194 | 62 |
| Tramadol Hcl | Tramadol Hcl | 191 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 185 | 49 |
| Jardiance | Empagliflozin | 173 | 32 |
| Methylprednisolone | Methylprednisolone | 172 | 112 |
| Azithromycin | Azithromycin | 169 | 98 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 37 |
| Ezetimibe | Ezetimibe | 156 | 45 |
| Divalproex Sodium | Divalproex Sodium | 148 | 35 |
| Myrbetriq | Mirabegron | 143 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 37 |
| Memantine Hcl | Memantine Hcl | 136 | 28 |
| Januvia | Sitagliptin Phosphate | 123 | 23 |
| Mirtazapine | Mirtazapine | 121 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 39 |
| Methocarbamol | Methocarbamol | 115 | 42 |
| Simvastatin | Simvastatin | 111 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 32 |
| Allopurinol | Allopurinol | 104 | 30 |
| Meloxicam | Meloxicam | 104 | 31 |
| Alprazolam | Alprazolam | 98 | 29 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 91 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 21 |
| Sucralfate | Sucralfate | 82 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 28 |
| Ozempic | Semaglutide | 81 | 18 |
| Levetiracetam | Levetiracetam | 80 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Glimepiride | Glimepiride | 68 | 20 |
| Levofloxacin | Levofloxacin | 68 | 47 |
| Warfarin Sodium | Warfarin Sodium | 68 | 11 |
| Prednisone | Prednisone | 66 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 23 |
| Latanoprost | Latanoprost | 63 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 63 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Spironolactone | Spironolactone | 58 | 20 |
| Temazepam | Temazepam | 58 | 16 |
| Benazepril Hcl | Benazepril Hcl | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 19 |
| Primidone | Primidone | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 15 |
| Atenolol | Atenolol | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 15 |
| Finasteride | Finasteride | 45 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 11 |
| Estradiol | Estradiol | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 13 |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Felodipine Er | Felodipine | 33 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 12 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Austedo | Deutetrabenazine | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | 13 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Mesalamine | Mesalamine | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tolvaptan | Tolvaptan | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,013.55 · 48 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, JARDIANCE, KISUNLA, Kerendia, Korlym, Leqembi, NEFFY, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error